Overview
Connections
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$40.2M
10 rounds on record
Latest round
$6.9M
Convertible Note · Mar 2026 · 7 mo ago
Team
51-200
employees, estimated range
Grants
$8M
4 grants · CORDIS
The money's age
Fresh money
7 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 24 Raised a round Convertible Note $6.9M · SEC Form D Oct 30, 2025 Raised a round Venture round $6.9M · SEC Form D Sep 8, 2023 Won a grant $1.8M · CORDIS Dec 28, 2022 Raised a round Venture round $12.8M · SEC Form D Sep 15, 2022 Won a grant $3.4M · CORDIS Apr 1, 2022 Raised a round Convertible Note $4M · SEC Form D Sep 30, 2020 Won a grant $2.5M · CORDIS Aug 26, 2020 Board appointment Jean-Pierre Million, Director · SEC Form D Apr 15, 2019 Won a grant $300k · CORDIS 2017 Founded
Funding rounds
RoundDateAmountInvestorsSource
Convertible Note Mar 2026 $6.9M — SEC Form D
Venture round Oct 2025 $6.9M — SEC Form D
Grant Sep 2023 $1.8M — CORDIS
Venture round Dec 2022 $12.8M — SEC Form D
Grant Sep 2022 $3.4M — CORDIS
Convertible Note Apr 2022 $4M — SEC Form D
Grant Sep 2020 $2.5M — CORDIS
Venture round Aug 2020 $4M — SEC Form D
Venture round Jun 2019 $5.8M — SEC Form D
Grant Apr 2019 $300k — CORDIS
Registers and programsofficial lists and records that name the company
Legal entity Alume Biosciences Inc SEC Form D
Founders and leadersfrom filings, registers and the company's site
Kaveri ParkerExecutive OfficerSEC Form D
Brett BermanExecutive Officer, DirectorSEC Form D
James SchmidtExecutive OfficerSEC Form D
Quyen NguyenExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
PreActivVenture round · 5 mo ago
Preactiv - An innovative platform that optimises patients before surgery using technology to create individualised prehabilitation…
Solstice OncologySeries A $225M · 1 mo ago · Founded 2026 · 51-200 employees
Solstice Oncology is a clinical stage immuno-oncology company developing a therapeutic that meets cancer at its most vulnerable moment…
Entirety Biomedical51-200 employees
Advanced Absorbable Metal TechnologyThe Next Standard of Care in Surgery Fixation. At Entirety Biomedical, we are passionate in our pursuit…
Andromeda Surgical51-200 employees · 5 roles
A smarter surgical platform. We're building the intelligence layer for surgery, starting with endourology.
SurgifyFounded 2017 · 11-50 employees
Surgify develops new solutions to protect these structures and prevent associated complications. Bleeding, infections and nerve injuries…
Driving Cost Savings. StreamliningSupply Chains.. Surgery Stuff is a trusted provider of high-quality surgical supplies for hospitals and…

Overview

Learn how Alume's proprietary nerve illumination technology can be applied in surgery to support surgeons. Before Surgery Patient receives ALM-488 through IV 60 minutes before surgery begins.

People

Kaveri Parker
Executive Officer
Brett Berman
Executive Officer, Director
James Schmidt
Executive Officer
Quyen Nguyen
Executive Officer, Director
Magda Marquet
Director
Kim Kamdar
Director
Jean-Pierre Millon
Director
Dan Bradbury
Director
Jean-Pierre Million
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters Builds here Office with open vacancies No open vacancies right now Tap a pin for the office
San Diego United States
HQ
La Jolla United States
Regional office
Hear more from our leaders and about Alume's technology
2223 Avenida de La Playa, Suite 205, La Jolla, CA 92037
company site

Financials

Total raised
$48.2M
Latest round
Convertible Note
Funding rounds
10
Funding rounds
Round Announced Amount
Convertible Note 2026 $6.9M Details
Venture - Series Unknown 2025 $6.9M Details
Grant 2023 $1.8M Details
Venture - Series Unknown 2022 $12.8M Details
Grant 2022 $3.4M Details
Convertible Note 2022 $4M Details
Grant 2020 $2.5M Details
Venture - Series Unknown 2020 $4M Details
Venture - Series Unknown 2019 $5.8M Details
Grant 2019 $300k Details